FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117834374> ?p ?o ?g. }

• W2117834374 endingPage "627" @default.
• W2117834374 startingPage "621" @default.
• W2117834374 abstract "We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy.Patients, aged > or =18 years, with pathologically confirmed ABC, Karnofsky performance (KP) > or =60, and adequate haematological, hepatic and renal function were randomised to G 1000 mg m(-2) on D1, 8, 15 q28d (Arm A) or C 25 mg m(-2) followed by G 1000 mg m(-2) D1, 8 q21d (Arm B) for up to 6 months or disease progression.In total, 86 patients (A/B, n=44/42) were randomised between February 2002 and May 2004. Median age (64/62.5 years), KP, primary tumour site, earlier surgery, indwelling biliary stent and disease stage (LA: 25/38%) are comparable between treatment arms. Grade 3-4 toxicity included (A/B, % patients) anaemia (4.5/2.4), leukopenia (6.8/4.8), neutropenia (13.6/14.3), thrombocytopenia (9.1/11.9), lethargy (9.1/28.6), nausea/vomiting (0/7.1) and anorexia (2.3/4.8). Responses (WHO criteria, % of evaluable patients: A n=31 vs B n=36): no CRs; PR 22.6 vs 27.8%; SD 35.5 vs 47.1% for a tumour control rate (CR+PR+SD) of 58.0 vs 75.0%. The median TTP and 6-month progression-free survival (PFS) (the primary end point) were greater in the C/G arm (4.0 vs 8.0 months and 45.5 vs 57.1% in arms A and B, respectively).Both regimens seem active in ABC. C/G is associated with an improved tumour control rate, TTP and 6-month PFS. The study has been extended (ABC-02 study) and powered to determine the effect on overall survival and the quality of life." @default.
• W2117834374 created "2016-06-24" @default.
• W2117834374 creator A5003454059 @default.
• W2117834374 creator A5010914696 @default.
• W2117834374 creator A5015401016 @default.
• W2117834374 creator A5018132206 @default.
• W2117834374 creator A5021439838 @default.
• W2117834374 creator A5029123237 @default.
• W2117834374 creator A5029890517 @default.
• W2117834374 creator A5042632184 @default.
• W2117834374 creator A5054875746 @default.
• W2117834374 creator A5060350068 @default.
• W2117834374 creator A5060816944 @default.
• W2117834374 creator A5063738443 @default.
• W2117834374 creator A5079189753 @default.
• W2117834374 creator A5080693514 @default.
• W2117834374 creator A5083063746 @default.
• W2117834374 creator A5083898918 @default.
• W2117834374 creator A5084931744 @default.
• W2117834374 creator A5085230100 @default.
• W2117834374 creator A5086349623 @default.
• W2117834374 date "2009-08-01" @default.
• W2117834374 modified "2023-10-17" @default.
• W2117834374 title "Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study" @default.
• W2117834374 cites W1921236192 @default.
• W2117834374 cites W1931508686 @default.
• W2117834374 cites W1989170359 @default.
• W2117834374 cites W2005019571 @default.
• W2117834374 cites W2019205795 @default.
• W2117834374 cites W2025769688 @default.
• W2117834374 cites W2046270680 @default.
• W2117834374 cites W2047318784 @default.
• W2117834374 cites W2055039012 @default.
• W2117834374 cites W2075383318 @default.
• W2117834374 cites W2076649038 @default.
• W2117834374 cites W2084562398 @default.
• W2117834374 cites W2089604747 @default.
• W2117834374 cites W2093388808 @default.
• W2117834374 cites W2095196969 @default.
• W2117834374 cites W2101036284 @default.
• W2117834374 cites W2103845052 @default.
• W2117834374 cites W2128889451 @default.
• W2117834374 cites W2129197203 @default.
• W2117834374 cites W2135352785 @default.
• W2117834374 cites W2139947970 @default.
• W2117834374 cites W2261129417 @default.
• W2117834374 cites W2319550695 @default.
• W2117834374 doi "https://doi.org/10.1038/sj.bjc.6605211" @default.
• W2117834374 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2736816" @default.
• W2117834374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19672264" @default.
• W2117834374 hasPublicationYear "2009" @default.
• W2117834374 type Work @default.
• W2117834374 sameAs 2117834374 @default.
• W2117834374 citedByCount "226" @default.
• W2117834374 countsByYear W21178343742012 @default.
• W2117834374 countsByYear W21178343742013 @default.
• W2117834374 countsByYear W21178343742014 @default.
• W2117834374 countsByYear W21178343742015 @default.
• W2117834374 countsByYear W21178343742016 @default.
• W2117834374 countsByYear W21178343742017 @default.
• W2117834374 countsByYear W21178343742018 @default.
• W2117834374 countsByYear W21178343742019 @default.
• W2117834374 countsByYear W21178343742020 @default.
• W2117834374 countsByYear W21178343742021 @default.
• W2117834374 countsByYear W21178343742022 @default.
• W2117834374 countsByYear W21178343742023 @default.
• W2117834374 crossrefType "journal-article" @default.
• W2117834374 hasAuthorship W2117834374A5003454059 @default.
• W2117834374 hasAuthorship W2117834374A5010914696 @default.
• W2117834374 hasAuthorship W2117834374A5015401016 @default.
• W2117834374 hasAuthorship W2117834374A5018132206 @default.
• W2117834374 hasAuthorship W2117834374A5021439838 @default.
• W2117834374 hasAuthorship W2117834374A5029123237 @default.
• W2117834374 hasAuthorship W2117834374A5029890517 @default.
• W2117834374 hasAuthorship W2117834374A5042632184 @default.
• W2117834374 hasAuthorship W2117834374A5054875746 @default.
• W2117834374 hasAuthorship W2117834374A5060350068 @default.
• W2117834374 hasAuthorship W2117834374A5060816944 @default.
• W2117834374 hasAuthorship W2117834374A5063738443 @default.
• W2117834374 hasAuthorship W2117834374A5079189753 @default.
• W2117834374 hasAuthorship W2117834374A5080693514 @default.
• W2117834374 hasAuthorship W2117834374A5083063746 @default.
• W2117834374 hasAuthorship W2117834374A5083898918 @default.
• W2117834374 hasAuthorship W2117834374A5084931744 @default.
• W2117834374 hasAuthorship W2117834374A5085230100 @default.
• W2117834374 hasAuthorship W2117834374A5086349623 @default.
• W2117834374 hasBestOaLocation W21178343741 @default.
• W2117834374 hasConcept C126322002 @default.
• W2117834374 hasConcept C141071460 @default.
• W2117834374 hasConcept C168563851 @default.
• W2117834374 hasConcept C203092338 @default.
• W2117834374 hasConcept C2776694085 @default.
• W2117834374 hasConcept C2777063308 @default.
• W2117834374 hasConcept C2777260799 @default.
• W2117834374 hasConcept C2780258809 @default.
• W2117834374 hasConcept C2780580376 @default.
• W2117834374 hasConcept C2780852908 @default.
• W2117834374 hasConcept C2780873365 @default.

• next